Generic Medicine Info
Indications and Dosage
Pain and inflammation
Adult: For relief of rheumatic pain, pain of non-serious arthritic conditions, and soft tissue injuries: As 3% gel or 3.17% foam: Gently rub approx 1 inch (2.5 cm) of gel or 1.5 inches (4 cm) of foam over affected area(s) 2-4 times daily. Max: 25 g daily (irrespective of the size or number of affected areas). Review therapy after 14 days.
Hypersensitivity (including patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs). Pregnancy and lactation.
Adverse Reactions
Significant: Asthma, renal disease, anaphylaxis (application of large amount).
Nervous: Paraesthesia.
GI: GI disturbance, dyspepsia.
Resp: Bronchospasm, dyspnoea, wheezing.
Dermatologic: Pruritus, rash, dermatitis, angioedema, purpura, epidermal necrolysis, erythema multiforme, photosensitivity, application site reactions.
Patient Counseling Information
Avoid application to broken skin, contact w/ eyes or mucous membranes, use of occlusive dressings, and excessive exposure of treated area to sunlight.
Drug Interactions
Increased incidence of adverse reactions w/ aspirin or other NSAIDs.
Description: Felbinac is the active metabolite of fenbufen. It is used topically for local treatment of pain and inflammation of the musculoskeletal system.
Absorption: Topical application results in low circulating levels of felbinac.
Distribution: Distributed preferentially to site of inflammation.
Store below 25°C.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M02AA08 - felbinac ; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.
Buckingham R (ed). Felbinac. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/02/2017.

Joint Formulary Committee. Felbinac. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/02/2017.

Disclaimer: This information is independently developed by MIMS based on Felbinac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in